{
    "clinical_study": {
        "@rank": "20280", 
        "arm_group": {
            "arm_group_label": "rhTPO-Derived Autologous Platelets Transfusion", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "A Pilot Study of Transfusion of rhTPO-Derived Autologous Platelets Cryopreserved with\n      ThromboSol and 2% DMSO in Patients with Gynecologic Malignancy Receiving Carboplatin"
        }, 
        "brief_title": "rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin", 
        "completion_date": {
            "#text": "June 2004", 
            "@type": "Actual"
        }, 
        "condition": "Neoplasms, Gynecologic", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Genital Neoplasms, Female"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA:\n\n          -  Patients with gynecologic malignancy for whom treatment with carboplatin is\n             indicated.\n\n          -  Age >/= 15 years.\n\n          -  Adequate hematologic, renal, and hepatic functions.\n\n          -  Life expectancy >/- 3 months. Karnofsky Performance Status >/= 80.\n\n          -  Signed informed consent form.\n\n        EXCLUSION CRITERIA:\n\n          -  Patients with rapidly progressive disease.\n\n          -  Pregnant or lactating women.\n\n          -  Patients with comorbid condition which renders patients at high risk of treatment\n             complication.\n\n          -  History of CNS metastasis.\n\n          -  Patients with significant cardiac disease (NYHA Class III or IV), dysrhythmia, or\n             recent history of MI or ischemia, transient ischemic attack or CVA within the 6\n             months of study entry.\n\n          -  Prior chemotherapy, immunotherapy, any experimental drug within 4 weeks, use of\n             myeloid (G-CSF or GM-CSF) growth factors within 2 weeks or erythropoietin within 4\n             weeks.\n\n          -  Use of any nitrosourea (BCNU, CCNU) or mitomycin - C within 6 weeks.\n\n          -  Prior surgery or RT within 2 wks of study entry.\n\n          -  Patients with history of prior high dose chemotherapy with stem cell transplant or\n             with history of prolonged thrombocytopenia (> 2 weeks).\n\n          -  History of leukemia.\n\n          -  History of any platelet disorders including ITP, TTP or bleeding disorders.\n\n          -  History of > 3 prior chemotherapy regimens (all platinum regimens will be counted as\n             1 regimen).\n\n          -  Demonstrated lack of response to platinum-based therapy."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 24, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00038012", 
            "org_study_id": "GYN97-310"
        }, 
        "intervention": [
            {
                "arm_group_label": "rhTPO-Derived Autologous Platelets Transfusion", 
                "intervention_name": "Thrombopoietin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "rhTPO-Derived Autologous Platelets Transfusion", 
                "intervention_name": "Platelet-pheresis", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "rhTPO-Derived Autologous Platelets Transfusion", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug", 
                "other_name": "Paraplatin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Carboplatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Dose-intensified carboplatin", 
            "autologous cryopreserved platelets", 
            "thrombopoietin", 
            "Gynecologic malignancy"
        ], 
        "lastchanged_date": "July 31, 2012", 
        "link": {
            "description": "UT MD Anderson Cancer Center website", 
            "url": "http://www.mdanderson.org"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "MD Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study of Transfusion of rhTPO-Derived Autologous Platelets Cryopreserved With Thrombosol and 2% DMSO in Patients With Gynecologic Malignancy Receiving Carboplatin", 
        "overall_official": {
            "affiliation": "UT MD Anderson Cancer Center", 
            "last_name": "Saroj Vadhan-Raj, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Response Rate", 
            "safety_issue": "No", 
            "time_frame": "Continuous"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00038012"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "M.D. Anderson Cancer Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Pharmacia", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "LifeCell", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "M.D. Anderson Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 1999", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }, 
    "geocoordinates": {
        "MD Anderson Cancer Center": "29.76 -95.369"
    }
}